<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28367163</article-id><article-id pub-id-type="pmc">5368334</article-id><article-id pub-id-type="publisher-id">PJMS-33-8</article-id><article-id pub-id-type="doi">10.12669/pjms.331.11764</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Therapeutic effects of metformin and clomiphene in combination with lifestyle intervention on infertility in women with obese polycystic ovary syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Si</surname><given-names>Qinqin</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jinqiong</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Dr. Jing Zhang, Department of Obstetrics and Gynecology, Affiliated Heji Hospital of Changzhi College of Medicine, Changzhi 046000, P. R. China</aff><aff id="aff2"><label>2</label>Dr. Qinqin Si, Department of Endocrinology, Affiliated Heji Hospital of Changzhi College of Medicine, Changzhi 046000, P. R. China</aff><aff id="aff3"><label>3</label>Dr. Jinqiong Li, Department of Obstetrics and Gynecology, Affiliated Heji Hospital of Changzhi College of Medicine, Changzhi 046000, P. R. China</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence:</italic></bold> Dr. Jing Zhang, Affiliated Heji Hospital of Changzhi College of Medicine, Changzhi 046000, P. R. China. E-mail: <email xlink:href="zhangjingahh@hotmail.com">zhangjingahh@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2017</year></pub-date><volume>33</volume><issue>1</issue><fpage>8</fpage><lpage>12</lpage><history><date date-type="received"><day>26</day><month>10</month><year>2016</year></date><date date-type="rev-recd"><day>09</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To evaluate the therapeutic effects of metformin and clomiphene in combination with lifestyle adjustment on infertility in women with obese polycystic ovarian syndrome (PCOS).</p></sec><sec id="st2"><title>Methods:</title><p>A total of 101 infertile women with obese PCOS admitted to our hospital from July 2013 to July 2015 were randomly divided into an observation group (n=51) and a control group (n=50). The control group was treated with metformin plus clomiphene, based on which the observation group was also subjected to lifestyle adjustment. The body weight, body mass index (BMI) and waist-to-hip ratio (WHR) were measured before and after treatment. The changes of reproductive hormones, ovaries and endometrium were detected, and the rates of menstrual recovery, ovulation and pregnancy were observed.</p></sec><sec id="st3"><title>Results:</title><p>The body weight and BMI of the observation group after treatment were significantly lower than those before treatment and of the control group (P&#x0003c;0.05). There was no significant difference in WHR between the two groups. In the observation group, there were significant differences in LH, T, LH/FSH, FINS and TG levels before and after treatment and from those of the control group after treatment (P&#x0003c;0.05). Both the left and right ovarian volumes of the observation group after treatment were significantly lower than those before treatment and of the control group after treatment (P&#x0003c;0.05). The menstrual recovery, ovulation and pregnancy rates of the observation group were significantly higher than those of the control group (P&#x0003c;0.05).</p></sec><sec id="st4"><title>Conclusion:</title><p>Lifestyle adjustment combined with metformin and clomiphene can improve the reproductive endocrine and lipid metabolism of obese PCOS patients, decrease the volumes of left and right ovaries, and increase the menstrual recovery, ovulation and pregnancy rates.</p></sec></abstract><kwd-group><kwd>Obesity</kwd><kwd>Clomiphene</kwd><kwd>Infertility</kwd><kwd>Lifestyle Intervention</kwd><kwd>Metformin</kwd><kwd>Polycystic ovary syndrome</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Polycystic ovarian syndrome (PCOS) is an endocrine disorder with coexisting glucose metabolism abnormalities and reproductive dysfunction, with complex clinical symptoms as well as unclear etiology and pathogenesis. PCOS is clinically typified by androgen excess and chronic anovulation, manifested as menstrual disorders, hypomenorrhea, amenorrhea, obesity, infertility, hirsutism, acne, etc. At present, PCOS has mainly been associated with adrenal dysfunction, hypothalamic-pituitary dysfunction,<xref rid="ref1" ref-type="bibr">1</xref> insulin resistance, genetic factors, etc. In addition, the disease is often complicated by metabolic abnormalities of other tissues, increasing the risk of cardiovascular diseases and endometrial cancer. As a result, the life, mental and physical healths of patients are severely affected. Currently, PCOS is generally clinical treated by taking oral contraceptives and insulin, but the therapeutic effects remain unsatisfactory.<xref rid="ref2" ref-type="bibr">2</xref> This study assessed the effects of metformin and clomiphene in combination with lifestyle adjustment on infertility in obese PCOS patients by observing the changes of reproductive endocrine and lipid metabolism.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>Baseline clinical data</title><p>A total of 101 infertile women with obese PCOS admitted to our hospital from July 2013 to July 2015 were selected, who were aged 22-34 years old, with a mean age of (27.8 &#x000b1; 4.6). The durations of infertility ranged from 2 to 5 years, (3.08 &#x000b1; 0.81) on average. All patients were randomly divided into an observation group (n=51) and a control group (n=50). In the observation group, the patients were aged 23-35 years old, with a mean age of (28.3 &#x000b1; 5.1). The durations of infertility ranged from 2 to 6 years, (3.54 &#x000b1; 0.79) years on average. In the control group, the patients were aged 24-36 years old, with a mean age of (27.8 &#x000b1; 5.4). The durations of infertility ranged from 2 to 5 years, (3.12 &#x000b1; 0.78) years on average. The two groups had similar duration of infertility and age (P&#x0003e;0.05). This study has been approved by the ethics committee of our hospital, and written consent has been obtained from all patients.</p></sec><sec id="sec2-2"><title>Diagnostic criteria</title><p>The criteria recommended by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) at the Rotterdam Conference in 2003 were used:<xref rid="ref3" ref-type="bibr">3</xref></p><p>
<list list-type="simple"><list-item><label>1)</label><p>Sporadic ovulation or anovulation</p></list-item><list-item><label>2)</label><p>Clinical manifestations of hyperandrogenism and/or hyperandrogenemia</p></list-item><list-item><label>3)</label><p>Ovarian polycystic changes: &#x02265;12 follicles on one or both sides with ovarian diameters of 2-9 mm, and (or) ovarian volume &#x02265;10 mL. Two of the three criteria were met, and other causes for hyperandrogenism, such as congenital adrenal hyperplasia, Cushing&#x02019;s syndrome and tumors with androgen secretion, were excluded.</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Methods</title><p>The control group was started on orally taken metformin (Guizhou Tian&#x02019;an Pharmaceutical Co., Ltd., National Medicine Permit No.H52020469) on the 1st-3rd days from menstruation or withdrawal bleeding, 500 mg/time, 3 times/day.<xref rid="ref4" ref-type="bibr">4</xref> It was taken after or at meal for three consecutive menstrual cycles. The patients began to additionally take clomiphene from the 5th day of the 4th menstrual cycle (Shanghai Hengshan Pharmaceutical Co., Ltd., National Medicine Permit No.H31021107), 50-100 mg/time, once/day. It was taken for 5 consecutive days and for 3 consecutive menstrual cycles.</p><p>The observation group received lifestyle adjustment on the basis of the control group:</p><p>
<list list-type="simple"><list-item><label>1)</label><p><bold><italic>Low-fat diet:</italic></bold> Carbohydrates mainly included oats and ordinary Japanese rice, with oil intake limited and fat and fried foods avoided; proteins were mainly derived from plants, fish and shrimp.</p></list-item><list-item><label>2)</label><p><bold><italic>Exercise strengthening:</italic></bold> Exercise with unlimited forms was taken once (at least 30 min each time) in the morning and evening respectively and stopped when the patients began to sweat, which lasted for 6 consecutive months.</p></list-item><list-item><label>3)</label><p><bold><italic>Smoking and drinking</italic></bold> were forbidden, and the patients were followed up at regular intervals.</p></list-item></list>
</p></sec><sec id="sec2-4"><title>Observation indices</title><p>
<list list-type="simple"><list-item><label>1)</label><p>The body weight, body mass index (BMI) and waist-to-hip ratio (WHR) were measured before and after treatment. BMI = Body mass (kg)/(height (m))<sup>2</sup>; WHR = waist circumference (cm)/hip circumference (cm).</p></list-item><list-item><label>2)</label><p>Determination of reproductive hormones: Fasting venous blood was drawn on the 3rd-5th days of the menstrual cycle or during the early follicular phase by B-ultrasonography. The levels of luteinizing hormone (LH), testosterone (T), follicle-stimulating hormone (FSH), fasting insulin (FINS) and triglyceride (TG) were measured by immunofluorescence assay. The kits with eligible inner- and inter-batch errors were all purchased from Bayer Diagnostics Ltd. (Hong Kong, China).</p></list-item><list-item><label>3)</label><p>The changes of ovaries and endometrium were detected by B-ultrasonography.</p></list-item><list-item><label>4)</label><p>The menstrual recovery, ovulation and pregnancy rates of obese PCOS patients were observed six months after treatment.</p></list-item></list>
</p></sec><sec id="sec2-5"><title>Statistical analysis</title><p>All data were analyzed by SPSS18.0, and subjected to one-way analysis of variance and variance homogeneity test. In the case of homogeneous variance, the LSD method was combined with the SNK method. The categorical data were expressed as (ax&#x000b1;s) and compared by the t test. The numerical data were compared by the &#x003c7;<sup>2</sup> test. P&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-6"><title>Clinical therapeutic effects</title><p>There was no significant difference in WHR between the two groups. The body weight and BMI of the observation group after treatment were significantly lower than those before treatment and of the control group (P&#x0003c;0.05) (<xref ref-type="table" rid="T1">Table-I</xref>).</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Clinical therapeutic effects.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" colspan="2" rowspan="1">Body weight (kg)</th><th align="center" colspan="2" rowspan="1">BMI (kg/m<sup>2</sup>)</th><th align="center" colspan="2" rowspan="1">WHR</th></tr><tr><th align="center" colspan="8" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">After treatment</th><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">After treatment</th><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">After treatment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">59.85&#x000b1;4.25</td><td align="center" rowspan="1" colspan="1">52.33&#x000b1;3.69<sup><xref ref-type="table-fn" rid="t1f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">22.96&#x000b1;2.45</td><td align="center" rowspan="1" colspan="1">20.30&#x000b1;2.24<sup><xref ref-type="table-fn" rid="t1f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">0.84&#x000b1;0.26</td><td align="center" rowspan="1" colspan="1">0.81&#x000b1;0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">60.09&#x000b1;4.13</td><td align="center" rowspan="1" colspan="1">57.35&#x000b1;3.86</td><td align="center" rowspan="1" colspan="1">23.36&#x000b1;2.36</td><td align="center" rowspan="1" colspan="1">22.12&#x000b1;2.32</td><td align="center" rowspan="1" colspan="1">0.86&#x000b1;0.24</td><td align="center" rowspan="1" colspan="1">0.83&#x000b1;0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.689</td><td align="center" rowspan="1" colspan="1">7.557</td><td align="center" rowspan="1" colspan="1">0.691</td><td align="center" rowspan="1" colspan="1">4.403</td><td align="center" rowspan="1" colspan="1">0.359</td><td align="center" rowspan="1" colspan="1">0.625</td></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="t1f1"><label>&#x025b2;</label><p>Compared with the data before treatment, P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-7"><title>Changes in reproductive endocrine and lipid metabolism indices</title><p>In the observation group, there were significant differences in LH, T, LH/FSH, FINS and TG levels before and after treatment (P&#x0003c;0.05). The control group had significantly different LH, T and LH/FSH levels before and after treatment (P&#x0003c;0.05). After treatment, the two groups also had significantly different LH, T, LH/FSH, FINS and TG levels (P&#x0003c;0.05) (<xref ref-type="table" rid="T2">Table-II</xref>).</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Changes in reproductive endocrine and lipid metabolism indices.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">LH (mIU/mL)</th><th align="center" rowspan="1" colspan="1">T (ng/mL)</th><th align="center" rowspan="1" colspan="1">LH/FSH</th><th align="center" rowspan="1" colspan="1">FINS (mIU/L)</th><th align="center" rowspan="1" colspan="1">TG (mmol/L)</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1"><italic>Observation (n=51)</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Before treatment</td><td align="center" rowspan="1" colspan="1">16.52&#x000b1;5.58</td><td align="center" rowspan="1" colspan="1">3.02&#x000b1;0.82</td><td align="center" rowspan="1" colspan="1">1.92&#x000b1;0.28</td><td align="center" rowspan="1" colspan="1">37.85&#x000b1;7.65</td><td align="center" rowspan="1" colspan="1">1.89&#x000b1;0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">After treatment</td><td align="center" rowspan="1" colspan="1">6.58&#x000b1;1.35<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup><xref ref-type="table-fn" rid="t2f2">*</xref></td><td align="center" rowspan="1" colspan="1">0.95&#x000b1;0.13<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup><xref ref-type="table-fn" rid="t2f2">*</xref></td><td align="center" rowspan="1" colspan="1">1.23&#x000b1;0.18<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup><xref ref-type="table-fn" rid="t2f2">*</xref></td><td align="center" rowspan="1" colspan="1">20.21&#x000b1;4.30<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup><xref ref-type="table-fn" rid="t2f2">*</xref></td><td align="center" rowspan="1" colspan="1">1.47&#x000b1;0.23<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup><xref ref-type="table-fn" rid="t2f2">*</xref></td></tr><tr><td align="left" colspan="6" rowspan="1"><italic>Control (n=50)</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Before treatment</td><td align="center" rowspan="1" colspan="1">16.70&#x000b1;5.48</td><td align="center" rowspan="1" colspan="1">3.03&#x000b1;0.78</td><td align="center" rowspan="1" colspan="1">1.95&#x000b1;0.30</td><td align="center" rowspan="1" colspan="1">38.14&#x000b1;7.42</td><td align="center" rowspan="1" colspan="1">2.06&#x000b1;0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">After treatment</td><td align="center" rowspan="1" colspan="1">7.03&#x000b1;1.41<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">1.25&#x000b1;0.20<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">1.42&#x000b1;0.20<sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">30.89&#x000b1;4.21</td><td align="center" rowspan="1" colspan="1">1.82&#x000b1;0.22</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="t2f1"><label>&#x025b2;</label><p>Compared with the data of the same group before treatment, P&#x0003c;0.05;</p></fn><fn id="t2f2"><label>*</label><p>compared with control group after treatment, P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-8"><title>Changes in ovaries and endometrium</title><p>Both the left and right ovarian volumes of the observation group after treatment were significantly lower than those before treatment and of the control group after treatment (P&#x0003c;0.05) (<xref ref-type="table" rid="T3">Table-III</xref>).</p><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Changes in ovaries and endometrium.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" colspan="2" rowspan="1">Left ovarian volume (mL)</th><th align="center" colspan="2" rowspan="1">Right ovarian volume (mL)</th><th align="center" colspan="2" rowspan="1">Endometrial thickness (mm)</th></tr><tr><th align="center" colspan="8" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">After treatment</th><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">After treatment</th><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">After treatment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">8.56&#x000b1;2.56</td><td align="center" rowspan="1" colspan="1">5.63&#x000b1;1.25<sup><xref ref-type="table-fn" rid="t3f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">8.32&#x000b1;2.62</td><td align="center" rowspan="1" colspan="1">5.45&#x000b1;1.09<sup><xref ref-type="table-fn" rid="t3f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">6.79&#x000b1;2.60</td><td align="center" rowspan="1" colspan="1">6.35&#x000b1;2.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">8.63&#x000b1;2.48</td><td align="center" rowspan="1" colspan="1">6.72&#x000b1;1.34</td><td align="center" rowspan="1" colspan="1">8.29&#x000b1;2.58</td><td align="center" rowspan="1" colspan="1">7.08&#x000b1;1.32</td><td align="center" rowspan="1" colspan="1">6.72&#x000b1;2.45</td><td align="center" rowspan="1" colspan="1">6.34&#x000b1;2.43</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.262</td><td align="center" rowspan="1" colspan="1">3.175</td><td align="center" rowspan="1" colspan="1">0.676</td><td align="center" rowspan="1" colspan="1">5.213</td><td align="center" rowspan="1" colspan="1">0.529</td><td align="center" rowspan="1" colspan="1">0.566</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="t3f1"><label>&#x025b2;</label><p>Compared with the data of the same group before treatment, P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-9"><title>Menstrual recovery, ovulation and pregnancy rates</title><p>The menstrual recovery, ovulation and pregnancy rates of the observation group significantly exceeded those of the control group (P&#x0003c;0.05) (<xref ref-type="table" rid="T4">Table-IV</xref>).</p><table-wrap id="T4" position="float"><label>Table-IV</label><caption><p>Menstrual recovery, ovulation and pregnancy rates.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">Menstrual recovery rate</th><th align="center" rowspan="1" colspan="1">Ovulation rate</th><th align="center" rowspan="1" colspan="1">Pregnancy rate</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">48 (94.12)</td><td align="center" rowspan="1" colspan="1">40 (78.43)</td><td align="center" rowspan="1" colspan="1">18 (35.29)</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">32 (64.00)</td><td align="center" rowspan="1" colspan="1">25 (50.00)</td><td align="center" rowspan="1" colspan="1">6 (12.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17.524</td><td align="center" rowspan="1" colspan="1">15.128</td><td align="center" rowspan="1" colspan="1">9.425</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-10"><title>Adverse reactions</title><p>At the beginning of medication, both groups suffered from gastrointestinal reactions such as nausea, vomiting and abdominal discomfort that disappeared after two weeks. During the first course of treatment, three cases of the observation group had small amounts of vaginal bleeding which stopped spontaneously.</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>PCOS is the most common cause of menstrual disorders in women of reproductive age. The incidence of women in the reproductive period is about 5%-10%, but its etiology has not been fully clear yet.<xref rid="ref5" ref-type="bibr">5</xref> Endocrine disorders are the main clinical features of patients with PCOS, mainly manifested as increase of LH, LH/FSH and T at varying degrees, of which the reason may be the increased pituitary sensitivity to gonadotropin-releasing hormones, resulting in excessive LH secretion. Excessive LH can also stimulate theca cells and ovarian stroma to secret excessive androgen.<xref rid="ref6" ref-type="bibr">6</xref> Due to the above mechanisms, the ovarian androgen levels of PCOS patients were significantly higher than those of the normal women, and the follicle maturation process is inhibited, but the small follicles in the ovaries of patients can still secrete a certain amount of E2. At the same time, androstenedione can be transformed into estrone in peripheral tissues, and E2 and estrone can act on the hypothalamus and pituitary, whose positive feedback can lead to increased amplitude and frequency of LH secretion.<xref rid="ref7" ref-type="bibr">7</xref></p><p>The patients are sustained with high levels of LH, with no cyclical changes, so PCOS patients have no occurrence of anovulation. In addition, about 50% of PCOS patients also have varying degrees of insulin resistance, with a very complex mechanism. The molecular mechanism is mainly related to multiple aspects such as pre-receptor, receptor-level and post-receptor insulin resistance.<xref rid="ref8" ref-type="bibr">8</xref> The excess insulin in PCOS patients can act on the pituitary insulin receptor, enhance the release of LH and promote the adrenal gland and ovarian androgen secretion, so as to further aggravate the patients&#x02019; condition.<xref rid="ref9" ref-type="bibr">9</xref></p><p>About 40%-60% of PCOS patients have symptoms of obesity that is more prone to hyperinsulinemia and insulin resistance, among which the three are closely linked with each other.<xref rid="ref8" ref-type="bibr">8</xref> Therefore, the lifestyle should be adjusted at first, and attention paid to diet and exercise to help patients lose weight, reduce the indicators of blood insulin, triglyceride and testosterone, increase sex hormone-binding globulin, which are all conducive to the ovulation and conception of obese PCOS patients and reduce the rate of abortion.<xref rid="ref10" ref-type="bibr">10</xref>-<xref rid="ref12" ref-type="bibr">12</xref> Decrease in BMI plays a favorable role in pregnancy outcomes and the improvement of endocrine and metabolic disorders.<xref rid="ref13" ref-type="bibr">13</xref> In this study, there was no significant difference in WHR between the two groups before and after treatment (P&#x0003e;0.05).</p><p>Since metformin was used to treat PCOS for the first time in 1994, many clinical studies have been performed. As an insulin-sensitive drug, metformin improves glucose metabolisms by promoting glucose absorption in the intestinal tract, reducing abnormal production of hepatic glycogen, facilitating anaerobic glycolysis and increasing glucose uptake and utilization by peripheral tissues such as muscles. As a result, the sensitivity to insulin is augmented, and the blood sugar level is decreased, accompanied by improved WHR.<xref rid="ref14" ref-type="bibr">14</xref> Meanwhile, insulin resistance-induced compensatory hyperinsulinemia was mitigated. Decrease in insulin level lowers those of LH and androgen as well as LH/FSH, helps correct hirsutism and acne, and recovers ovulatory menstruation.<xref rid="ref15" ref-type="bibr">15</xref> Palomba et al.<xref rid="ref16" ref-type="bibr">16</xref> found that the cumulative ovulation rate using metformin was similar to that using clomiphene, but the former led to higher rates of pregnancy and live birth.</p><p>In the observation group of metformin and clomiphene combined with lifestyle adjustment (including low-fat diet, exercise strengthening and forbidding of smoking and drinking), the weight and BMI after treatment were significantly lower than those before treatment and of the control group (metformin and clomiphene only) after treatment, among which the differences were statistically significant (P&#x0003c;0.05). Thus, the combination of metformin and clomiphene with lifestyle adjustment evidently reduced body weight, BMI and WHR. In the observation group, there were significant differences in LH, T, LH/FSH, FINS and TG levels before and after treatment (P&#x0003c;0.05).</p><p>In the control group, the differences in LH, T and LH/FSH were all significant between before and after treatment (P&#x0003c;0.05). After treatment, the two groups also had significantly different LH, T, LH/FSH, FINS and TG levels (P&#x0003c;0.05). Both the left and right ovarian volumes of the observation group after treatment were significantly lower than those before treatment and of the control group after treatment, with the differences being statistically significant (P&#x0003c;0.05). The menstrual recovery rate, ovulation rate and pregnancy rate of the observation group were significantly higher than those of the control group (P&#x0003c;0.05). Hence, for PCOS patients, the combination of medication with lifestyle adjustment had better effects than absolute medicine therapy, which could reduce body weight, regulate endocrine and metabolic disorders, restore menstruation to normal and improve ovulation rate.</p><p>In summary, lifestyle adjustment combined with metformin and clomiphene can significantly relieve insulin sensitivity of infertile patients with PCOS, lower BMI, regulate endocrine and metabolic disorders, recover menstruation to normal and elevate ovulation rate, as an ideal method for the treatment of PCOS-induced infertility.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold><italic>Source of funding:</italic></bold> Health Department of Shanxi Province Foundation (No. 2015134).</p></fn></fn-group><sec id="sec1-5"><title/><sec id="sec2-11"><title>Authors&#x02019; Contribution</title><p><bold>JZ &#x00026; QS</bold> conceived, designed and did statistical analysis &#x00026; editing of manuscript.</p><p><bold>QS &#x00026; JL</bold> did data collection and manuscript writing.</p><p><bold>JZ</bold> did review and final approval of manuscript.</p><p><bold>JZ</bold> takes the responsibility and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></sec></sec><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghazeeri</surname><given-names>G</given-names></name><name><surname>Kutteh</surname><given-names>WH</given-names></name><name><surname>Bryer-Ash</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>D</given-names></name><name><surname>Ke</surname><given-names>RW</given-names></name></person-group><article-title>Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2003</year><volume>79</volume><issue>3</issue><fpage>562</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">12620440</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Leo</surname><given-names>V</given-names></name><name><surname>Musacchio</surname><given-names>MC</given-names></name><name><surname>Palermo</surname><given-names>V</given-names></name><name><surname>Di Sabatino</surname><given-names>A</given-names></name><name><surname>Morgante</surname><given-names>G</given-names></name><name><surname>Petraglia</surname><given-names>F</given-names></name></person-group><article-title>Polycystic ovary syndrome and metabolic comorbidities: therapeutic options</article-title><source>Drugs Today (Barc)</source><year>2009</year><volume>45</volume><issue>10</issue><fpage>763</fpage><lpage>775</lpage><comment>doi:1396674/dot.2009.45.10.1429463</comment><pub-id pub-id-type="pmid">20069140</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><collab>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</collab><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2004</year><volume>81</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legro</surname><given-names>RS</given-names></name><name><surname>Barnhart</surname><given-names>HX</given-names></name><name><surname>Schlaff</surname><given-names>WD</given-names></name><name><surname>Carr</surname><given-names>BR</given-names></name><name><surname>Diamond</surname><given-names>MP</given-names></name><name><surname>Carson</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>6</issue><fpage>551</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17287476</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Hahn</surname><given-names>S</given-names></name><name><surname>Benson</surname><given-names>S</given-names></name><name><surname>Dietz</surname><given-names>T</given-names></name><name><surname>Lahner</surname><given-names>H</given-names></name><name><surname>Moeller</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance</article-title><source>Eur J Endocrinol</source><year>2007</year><volume>157</volume><issue>5</issue><fpage>669</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">17984248</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusco</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>A</given-names></name><name><surname>Mancini</surname><given-names>A</given-names></name><name><surname>Milardi</surname><given-names>D</given-names></name><name><surname>Giampietro</surname><given-names>A</given-names></name><name><surname>Cimino</surname><given-names>V</given-names></name><etal/></person-group><article-title>Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome</article-title><source>J Endocrinol Invest</source><year>2007</year><volume>30</volume><issue>11</issue><fpage>948</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">18250617</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Q</given-names></name><name><surname>Fischer</surname><given-names>L</given-names></name><name><surname>Noethling</surname><given-names>C</given-names></name><name><surname>Schaefer</surname><given-names>WR</given-names></name></person-group><article-title>In vitro-assessment of putative antiprogestin activities of phytochemicals and synthetic UV absorbers in human endometrial Ishikawa cells</article-title><source>Gynecol Endocrinol</source><year>2015</year><volume>31</volume><issue>7</issue><fpage>578</fpage><lpage>581</lpage><comment>doi:10.3109/09513590.2015.1047448</comment><pub-id pub-id-type="pmid">26036805</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Pasquali</surname><given-names>R</given-names></name><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Hoeger</surname><given-names>KM</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name></person-group><article-title>Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><issue>6</issue><fpage>1966</fpage><lpage>1982</lpage><comment>doi:10.1016/j.fertnstert.2008.09.018</comment><pub-id pub-id-type="pmid">19062007</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Hutchison</surname><given-names>SK</given-names></name><name><surname>Zoungas</surname><given-names>S</given-names></name><name><surname>McGrath</surname><given-names>BP</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name></person-group><article-title>Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy</article-title><source>Fertil Steril</source><year>2010</year><volume>93</volume><issue>1</issue><fpage>184</fpage><lpage>191</lpage><comment>doi:10.1016/j.fertnstert.2008.09.034</comment><pub-id pub-id-type="pmid">19019358</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>F</given-names></name></person-group><article-title>Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome</article-title><source>Reprod Biomed Online</source><year>2011</year><volume>23</volume><issue>1</issue><fpage>91</fpage><lpage>96</lpage><comment>doi:10.1016/j.rbmo.2011.03.024</comment><pub-id pub-id-type="pmid">21550852</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin-Papunen</surname><given-names>LC</given-names></name><name><surname>Vauhkonen</surname><given-names>I</given-names></name><name><surname>Koivunen</surname><given-names>RM</given-names></name><name><surname>Ruokonen</surname><given-names>A</given-names></name><name><surname>Martikainen</surname><given-names>HK</given-names></name><name><surname>Tapanainen</surname><given-names>JS</given-names></name></person-group><article-title>Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><issue>9</issue><fpage>3161</fpage><lpage>3168</lpage><pub-id pub-id-type="pmid">10999803</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>RB</given-names></name><name><surname>Tachotti</surname><given-names>F</given-names></name><name><surname>Cavenague</surname><given-names>G</given-names></name><name><surname>Maia</surname><given-names>E</given-names></name></person-group><article-title>Effects of two different oral contraceptives on total body water: a randomized study</article-title><source>Contraception</source><year>2006</year><volume>73</volume><issue>4</issue><fpage>344</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">16531163</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Effect analysis of metformin combined with clomiphene in the treatment of polycystic ovarian syndrome combined with infertility</article-title><source>Chinese Community Doctors</source><year>2014</year><volume>21</volume><fpage>78</fpage><lpage>80</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YQ</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>ZR</given-names></name><name><surname>Pen</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>GF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Clinical observation of marvelon combined with metformin in the treatment of 30 cases of pubertal polycystic ovary syndrome</article-title><source>Hainan Med J</source><year>2012</year><volume>23</volume><issue>15</issue><fpage>76</fpage><lpage>78</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motta</surname><given-names>DA</given-names></name></person-group><article-title>Metformin in the treatment of polycystic ovary syndrome</article-title><source>Curr Pharm Des</source><year>2008</year><volume>14</volume><issue>21</issue><fpage>2121</fpage><lpage>2125</lpage><pub-id pub-id-type="pmid">18691121</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomba</surname><given-names>S</given-names></name><name><surname>Orio</surname><given-names>F</given-names><suffix>Jr</suffix></name><name><surname>Falbo</surname><given-names>A</given-names></name><name><surname>Manguso</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>T</given-names></name><name><surname>Cascella</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><issue>7</issue><fpage>4068</fpage><lpage>4074</lpage><pub-id pub-id-type="pmid">15840746</pub-id></element-citation></ref></ref-list></back></article>